Matthew A Gubens, MD

Offices

4 locations · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gubens’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence A98645 · Current

Licensed to practise in California · since 2007 · expires 2028-09-30 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$602,973

Medicare paid this office $602,973 for 218 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	116	$58,763	$124
Return visit (30+ min)	70	$8,325	$82
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	159	$7,774	$15
New patient visit (60+ min)	30	$4,677	$156
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	46	$3,258	$28

See all 7 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	116	$58,763	$124
Return visit (30+ min)	70	$8,325	$82
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	159	$7,774	$15
New patient visit (60+ min)	30	$4,677	$156
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	46	$3,258	$28
Telephone medical discussion with physician, 21-30 minutes	14	$1,580	$83
Short return visit (20+ min)	25	$1,470	$54

Who their Medicare patients are

218 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 7% · Women 62% · Also on Medicaid 22% · Health risk score 2.26. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 65% · COPD 25% · Coronary heart disease 24% · Chronic kidney disease 23% · Atrial fibrillation 22% · Depression 22% · Diabetes 20% · Heart failure 14% · Stroke 10%.

The office billed $4,214,594, Medicare allowed $759,510 and paid $602,973; for 23,591 services of 45 kinds; $505,326 of it was for drugs given in the office and $97,647 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	218	23,591	74	2.26	$4,214,594	$602,973
2023	233	18,050	73	2.49	$2,860,434	$369,471
2022	211	1,882	73	2.49	$698,648	$109,607
2021	210	725	72	2.38	$503,073	$82,102
2020	188	727	72	2.27	$532,994	$69,035
2019	145	447	72	2.12	$352,681	$44,418
2018	111	261	73	2.65	$189,771	$25,175
2017	135	514	73	2.62	$357,474	$49,703
2016	149	609	73	2.41	$401,742	$54,123
2015	172	593	72	2.24	$372,707	$51,044
2014	179	651	73	2.12	$396,355	$56,071
2013	167	681	73	2.17	$381,907	$57,222

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	146	$66,717	$122
Return visit (30+ min)	54	$5,267	$76
New patient visit (60+ min)	34	$5,262	$155
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	60	$3,426	$27
Telephone medical discussion with physician, 21-30 minutes	16	$1,651	$83
Short return visit (20+ min)	24	$1,363	$55
Advance care planning, first 30 minutes	11	$953	$64

2022: 7 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	131	$64,547	$123
New patient visit (60+ min)	35	$5,712	$163
Return visit (30+ min)	41	$3,719	$70
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	50	$2,872	$28
Extended patient service without direct patient contact, first hour	22	$2,662	$99
Short return visit (20+ min)	20	$1,249	$59
Advance care planning, first 30 minutes	12	$1,053	$66

2021: 6 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	133	$65,764	$127
Return visit (30+ min)	51	$4,873	$83
New patient visit (60+ min)	29	$4,783	$165
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	28	$1,450	$29
Extended patient service without direct patient contact, first hour	12	$1,304	$100
Short return visit (20+ min)	15	$1,033	$61

2020: 4 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	145	$49,408	$97
Return visit (30+ min)	72	$7,138	$71
New patient visit (60+ min)	44	$6,658	$151
Extended patient service without direct patient contact, first hour	32	$3,971	$102

2019: 3 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	114	$35,562	$94
New patient visit (60+ min)	43	$6,485	$151
Extended patient service without direct patient contact, first hour	15	$1,512	$101

2018: 2 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	93	$21,635	$92
New patient visit (60+ min)	24	$3,463	$144

2017: 3 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	107	$42,929	$97
New patient visit (60+ min)	29	$4,174	$144
Return visit (30+ min)	23	$1,822	$63

2016: 4 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	70	$34,816	$93
Return visit (30+ min)	78	$10,902	$67
New patient visit (60+ min)	51	$7,464	$146
Short return visit (20+ min)	16	$802	$42

2015: 4 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	83	$27,288	$96
Return visit (30+ min)	94	$14,373	$66
New patient visit (60+ min)	50	$7,189	$144
Office for the evaluation and management of established patient that may not require presence of healthcare professional	12	$107	$8

2014: 5 services

Sort by

Original Medicare services billed in 2014

Long return visit (40+ min)	77	$28,051	$97
Return visit (30+ min)	93	$16,166	$68
New patient visit (60+ min)	57	$8,567	$150
Short return visit (20+ min)	18	$960	$46
Office for the evaluation and management of established patient that may not require presence of healthcare professional	26	$215	$8

2013: 6 services

Sort by

Original Medicare services billed in 2013

Long return visit (40+ min)	84	$28,936	$93
Return visit (30+ min)	87	$14,583	$65
New patient visit (60+ min)	67	$9,646	$144
New patient visit (30+ min)	17	$1,124	$66
Short return visit (20+ min)	11	$485	$44
Office for the evaluation and management of established patient that may not require presence of healthcare professional	28	$204	$7

Medicaid work

$4,656 in 2024

Medicaid paid $4,656 for 32 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Long return visit (40+ min)	32	$4,656

Sort by

Medicaid work by year

2024	32	1	15	$4,656
2023	101	1	17	$11,103
2022	31	1	14	$3,500
2021	229	1	21	$23,655
2020	164	1	15	$14,349
2018	76	1	17	$4,718

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Long return visit (40+ min)	101	$11,103

2022

Sort by

Largest Medicaid services in 2022

Long return visit (40+ min)	31	$3,500

2021

Sort by

Largest Medicaid services in 2021

Long return visit (40+ min)	229	$23,655

2020

Sort by

Largest Medicaid services in 2020

Long return visit (40+ min)	164	$14,349

2018

Sort by

Largest Medicaid services in 2018

Long return visit (40+ min)	76	$4,718

Drugs they prescribed that Part D paid

$1,862,542

Pharmacies billed $1,862,542 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

153 generic and fewer than 11 brand-name prescriptions · $1,862,542 in drug cost · 15 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Tagrisso	44	$716,933	$16,294
Alecensa	25	$298,809	$11,952
Tabrecta	13	$263,868	$20,298
Mekinist	12	$169,675	$14,140
Dexamethasone	22	$618	$28

See all 9 drugs

Sort by

Every Part D drug this clinician prescribed

Tagrisso	44	$716,933	$16,294
Alecensa	25	$298,809	$11,952
Tabrecta	13	$263,868	$20,298
Mekinist	12	$169,675	$14,140
Dexamethasone	22	$618	$28
Ondansetron	30	$362	$12
Prochlorperazine Maleate	21	$228	$11
Prednisone	11	$55	$5
Trazodone	11	$20	$2

Year by year

Sort by

Part D prescribing by year

2024	284	63	None	None	$1,862,542
2023	345	67	4% (15)	32%	$1,511,259
2022	381	67	4% (16)	28%	$1,569,128
2021	434	73	4% (18)	35%	$1,917,276
2020	459	73	6% (29)	31%	$1,360,279
2019	330	55	4% (13)	38%	$1,267,700
2018	322	52	4% (13)	36%	$1,171,685
2017	490	65	8% (37)	29%	$1,123,873
2016	627	57	7% (41)	None	$1,725,436
2015	552	57	8% (43)	28%	$891,342
2014	533	70	11% (56)	34%	$969,408
2013	518	69	13% (66)	36%	$919,836

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 5 drugs

Sort by

Part D drugs prescribed in 2023

Tagrisso	62	$1,054,414	$17,007
Eliquis	12	$15,316	$1,276
Ondansetron	56	$1,015	$18
Dexamethasone	26	$981	$38
Prochlorperazine Maleate	53	$778	$15

2022: 7 drugs

Sort by

Part D drugs prescribed in 2022

Tagrisso	62	$991,260	$15,988
Dexamethasone	34	$1,525	$45
Ondansetron	40	$761	$19
Prochlorperazine Maleate	30	$457	$15
Prednisone	17	$184	$11
Lorazepam	19	$129	$7
Sulfamethoxazole-Trimethoprim	11	$20	$2

2021: 9 drugs

Sort by

Part D drugs prescribed in 2021

Tagrisso	87	$1,434,307	$16,486
Xarelto	11	$8,976	$816
Eliquis	13	$8,960	$689
Ondansetron	54	$1,859	$34
Dexamethasone	37	$1,749	$47
Prochlorperazine Maleate	52	$730	$14
Potassium Chloride	21	$620	$30
Prednisone	16	$200	$13
Lorazepam	11	$47	$4

2020: 13 drugs

Sort by

Part D drugs prescribed in 2020

Tagrisso	71	$1,110,452	$15,640
Xarelto	14	$12,403	$886
Eliquis	11	$7,408	$673
Enoxaparin	11	$6,678	$607
Oxycodone	19	$1,212	$64
Dexamethasone	26	$910	$35
Prochlorperazine Maleate	45	$638	$14
Potassium Chloride	11	$637	$58
Ondansetron	31	$631	$20
Omeprazole	15	$460	$31
Levetiracetam	11	$315	$29
Lorazepam	38	$138	$4
Levothyroxine	12	$127	$11

2019: 8 drugs

Sort by

Part D drugs prescribed in 2019

Tagrisso	50	$810,949	$16,219
Alecensa	14	$217,550	$15,539
Tarceva	11	$92,541	$8,413
Xarelto	12	$5,824	$485
Dexamethasone	21	$734	$35
Ondansetron	17	$357	$21
Prochlorperazine Maleate	20	$250	$12
Lorazepam	23	$132	$6

2018: 10 drugs

Sort by

Part D drugs prescribed in 2018

Tagrisso	37	$575,358	$15,550
Tarceva	29	$259,348	$8,943
Alecensa	11	$168,928	$15,357
Enoxaparin	31	$12,398	$400
Dexamethasone	17	$409	$24
Ondansetron	16	$276	$17
Zolpidem Tartrate Er	14	$257	$18
Lorazepam	28	$175	$6
Prochlorperazine Maleate	12	$155	$13
Losartan	12	$33	$3

2017: 13 drugs

Sort by

Part D drugs prescribed in 2017

Tagrisso	29	$419,144	$14,453
Tarceva	47	$370,758	$7,888
Neulasta	12	$134,831	$11,236
Enoxaparin	26	$6,863	$264
Entecavir	12	$5,459	$455
Potassium Chloride	16	$821	$51
Ondansetron	24	$414	$17
Dexamethasone	18	$389	$22
Prochlorperazine Maleate	27	$296	$11
Levothyroxine	16	$234	$15
Lorazepam	39	$202	$5
Zolpidem Tartrate Er	12	$108	$9
Prednisone	19	$89	$5

2016: 20 drugs

Sort by

Part D drugs prescribed in 2016

Tagrisso	64	$912,789	$14,262
Tarceva	50	$347,137	$6,943
Alecensa	19	$238,002	$12,526
Gilotrif	13	$94,552	$7,273
Enoxaparin	28	$32,696	$1,168
Entecavir	12	$12,028	$1,002
Ondansetron	26	$5,319	$205
Clindamycin Phosphate	11	$1,245	$113
Oxycodone	20	$930	$46
Dexamethasone	39	$707	$18
Zolpidem Tartrate Er	11	$649	$59
Gabapentin	30	$436	$15
Lorazepam	53	$405	$8
Levetiracetam	12	$328	$27
Prednisone	12	$172	$14
Prochlorperazine Maleate	16	$146	$9
Hydrocortisone	13	$122	$9
Amlodipine Besylate	26	$97	$4
Omeprazole	11	$87	$8
Pantoprazole	13	$83	$6

2015: 17 drugs

Sort by

Part D drugs prescribed in 2015

Tarceva	90	$557,485	$6,194
Gilotrif	20	$134,145	$6,707
Enoxaparin	25	$32,926	$1,317
Ondansetron	43	$4,551	$106
Clindamycin Phosphate	23	$2,951	$128
Doxycycline Hyclate	18	$1,687	$94
Oxycodone-Acetaminophen	15	$1,441	$96
Oxycodone	16	$966	$60
Hydrocortisone	11	$798	$73
Dexamethasone	30	$323	$11
Lorazepam	40	$301	$8
Prochlorperazine Maleate	27	$248	$9
Gabapentin	29	$210	$7
Pantoprazole	11	$103	$9
Mirtazapine	11	$77	$7
Levetiracetam	12	$66	$5
Amlodipine Besylate	17	$66	$4

2014: 10 drugs

Sort by

Part D drugs prescribed in 2014

Tarceva	137	$796,571	$5,814
Enoxaparin	21	$32,808	$1,562
Clindamycin Phosphate	27	$4,196	$155
Doxycycline Hyclate	15	$1,587	$106
Ondansetron	36	$1,431	$40
Oxycodone	16	$876	$55
Hydrocodone-Acetaminophen	20	$716	$36
Dexamethasone	32	$510	$16
Prochlorperazine Maleate	37	$439	$12
Lorazepam	47	$356	$8

2013: 8 drugs

Sort by

Part D drugs prescribed in 2013

Tarceva	153	$790,672	$5,168
Ondansetron	43	$1,864	$43
Clindamycin Phosphate	14	$1,576	$113
Hydrocodone-Acetaminophen	29	$754	$26
Oxycodone	17	$731	$43
Prochlorperazine Maleate	43	$496	$12
Lorazepam	45	$359	$8
Dexamethasone	27	$345	$13

Money from drug and device companies

$30,909 in 2025

Sort by

Industry payments by year

2025	7	25	$28,833	$30,909
2024	5	20	$12,435	$13,908
2023	3	11	$9,700	$10,026
2022	4	4	$8,218	$8,341
2021	3	3	$7,523	$7,523
2020	3	24	$17,230	$19,754
2019	6	17	$15,138	$17,535

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

AstraZeneca Pharmaceuticals LP	Tagrisso	$11,750	5 payments Consulting for Imfinzi · 2025-11-06 · $4,920 Meals · 2025-10-10 · $135 Consulting for Tagrisso · 2025-07-11 · $2,050 Consulting for Tagrisso · 2025-07-01 · $4,510 Meals for Tagrisso · 2025-05-29 · $135
E.R. Squibb & Sons L.L.C.	None	$6,106	8 payments Consulting · 2025-08-04 · $1,390 Travel · 2025-03-31 · $89 Consulting · 2025-03-27 · $3,300 Meals · 2025-03-14 · $65 Meals · 2025-03-14 · $30 Meals · 2025-03-14 · $50 Travel · 2025-03-14 · $879 Travel · 2025-03-13 · $304
Janssen Biotech	Rybrevant	$4,929	6 payments Consulting for Rybrevant · 2025-12-11 · $1,670 Consulting for Rybrevant · 2025-06-30 · $1,500 Meals for Rybrevant · 2025-05-29 · $14 Meals for Rybrevant · 2025-05-29 · $94 Consulting for Rybrevant · 2025-03-13 · $1,500 Meals for Rybrevant · 2025-02-20 · $150
Beckman Coulter	None	$4,550	1 payment Consulting · 2025-12-23 · $4,550
Regeneron Healthcare Solutions	Libtayo	$2,318	2 payments Consulting for Libtayo · 2025-01-17 · $464 Consulting for Libtayo · 2025-01-17 · $1,854
Catalyst Pharmaceuticals	Firdapse	$1,152	2 payments Honoraria for Firdapse · 2025-02-21 · $1,125 Meals for Firdapse · 2025-02-21 · $27

See all 25 published payments

Sort by

Every published payment

Beckman Coulter	Consulting · 2025-12-23	None	$4,550
Janssen Biotech	Consulting · 2025-12-11	Rybrevant	$1,670
AstraZeneca Pharmaceuticals LP	Consulting · 2025-11-06	Imfinzi	$4,920
AstraZeneca Pharmaceuticals LP	Meals · 2025-10-10	None	$135
Genentech USA	Meals · 2025-09-06	Tecentriq	$104
E.R. Squibb & Sons L.L.C.	Consulting · 2025-08-04	None	$1,390
AstraZeneca Pharmaceuticals LP	Consulting · 2025-07-11	Tagrisso	$2,050
AstraZeneca Pharmaceuticals LP	Consulting · 2025-07-01	Tagrisso	$4,510
Janssen Biotech	Consulting · 2025-06-30	Rybrevant	$1,500
Janssen Biotech	Meals · 2025-05-29	Rybrevant	$14
Janssen Biotech	Meals · 2025-05-29	Rybrevant	$94
AstraZeneca Pharmaceuticals LP	Meals · 2025-05-29	Tagrisso	$135
E.R. Squibb & Sons L.L.C.	Travel · 2025-03-31	None	$89
E.R. Squibb & Sons L.L.C.	Consulting · 2025-03-27	None	$3,300
E.R. Squibb & Sons L.L.C.	Meals · 2025-03-14	None	$65
E.R. Squibb & Sons L.L.C.	Meals · 2025-03-14	None	$30
E.R. Squibb & Sons L.L.C.	Meals · 2025-03-14	None	$50
E.R. Squibb & Sons L.L.C.	Travel · 2025-03-14	None	$879
Janssen Biotech	Consulting · 2025-03-13	Rybrevant	$1,500
E.R. Squibb & Sons L.L.C.	Travel · 2025-03-13	None	$304
Catalyst Pharmaceuticals	Honoraria · 2025-02-21	Firdapse	$1,125
Catalyst Pharmaceuticals	Meals · 2025-02-21	Firdapse	$27
Janssen Biotech	Meals · 2025-02-20	Rybrevant	$150
Regeneron Healthcare Solutions	Consulting · 2025-01-17	Libtayo	$464
Regeneron Healthcare Solutions	Consulting · 2025-01-17	Libtayo	$1,854

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $13,908

Sort by

Payments by company in 2024

Janssen Biotech	Rybrevant	$5,519	6 payments Consulting for Rybrevant · 2024-10-11 · $1,400 Meals for Rybrevant · 2024-09-06 · $69 Consulting for Rybrevant · 2024-06-28 · $2,450 Meals for Rybrevant · 2024-05-31 · $65 Consulting for Rybrevant · 2024-03-15 · $1,400 Meals for Rybrevant · 2024-02-22 · $135
E.R. Squibb & Sons L.L.C.	None	$4,976	8 payments Travel · 2024-12-30 · $115 Consulting · 2024-11-26 · $3,500 Travel · 2024-11-14 · $288 Meals · 2024-11-07 · $56 Meals · 2024-11-07 · $25 Meals · 2024-11-07 · $43 Travel · 2024-11-07 · $399 Consulting · 2024-01-11 · $550
Genentech USA	Alecensa	$1,848	2 payments Meals for Alecensa · 2024-11-03 · $83 Consulting for Alecensa · 2024-11-03 · $1,765
AstraZeneca Pharmaceuticals LP	Tagrisso	$1,477	2 payments Consulting for Tagrisso · 2024-02-29 · $1,370 Meals for Tagrisso · 2024-02-23 · $107
Regeneron Healthcare Solutions	Libtayo	$88	2 payments Meals for Libtayo · 2024-11-15 · $59 Meals for Libtayo · 2024-11-15 · $29

2023: $10,026

Sort by

Payments by company in 2023

AstraZeneca Pharmaceuticals LP	Imfinzi	$5,602	5 payments Consulting for Imfinzi · 2023-12-07 · $1,713 Meals for Imfinzi · 2023-11-30 · $100 Consulting · 2023-10-27 · $2,055 Consulting for Imfinzi · 2023-03-06 · $1,663 Meals for Imfinzi · 2023-02-24 · $72
Gilead Sciences	None	$3,295	4 payments Consulting · 2023-02-24 · $3,170 Meals · 2023-02-22 · $48 Meals · 2023-02-22 · $48 Meals · 2023-02-22 · $28
E.R. Squibb & Sons L.L.C.	None	$1,130	2 payments Consulting · 2023-11-06 · $1,100 Meals · 2023-09-30 · $30

2022: $8,341

Sort by

Payments by company in 2022

Roche Diagnostics	None	$2,976	1 payment Consulting · 2022-12-01 · $2,976
Genentech USA	Tecentriq	$2,930	1 payment Consulting for Tecentriq · 2022-04-21 · $2,930
Genzyme	Libtayo	$2,312	1 payment Consulting for Libtayo · 2022-06-29 · $2,312
AstraZeneca Pharmaceuticals LP	Tagrisso	$123	1 payment Meals for Tagrisso · 2022-11-11 · $123

2021: $7,523

Sort by

Payments by company in 2021

AstraZeneca Pharmaceuticals LP	Imfinzi	$3,325	1 payment Consulting for Imfinzi · 2021-10-18 · $3,325
Genzyme	Libtayo	$2,108	1 payment Consulting for Libtayo · 2021-12-09 · $2,108
E.R. Squibb & Sons L.L.C.	Opdivo	$2,090	1 payment Consulting for Opdivo · 2021-07-19 · $2,090

2020: $19,754

Sort by

Payments by company in 2020

AstraZeneca Pharmaceuticals LP	Imfinzi	$15,872	13 payments Consulting for Tagrisso · 2020-12-01 · $3,325 Consulting for Tagrisso · 2020-06-30 · $1,330 Consulting for Imfinzi · 2020-06-22 · $3,350 Consulting for Imfinzi · 2020-01-23 · $6,650 Travel for Imfinzi · 2020-01-17 · $72 Meals for Imfinzi · 2020-01-17 · $48 Meals for Imfinzi · 2020-01-17 · $1 Meals for Imfinzi · 2020-01-17 · $35 Meals for Imfinzi · 2020-01-17 · $18 Meals for Imfinzi · 2020-01-17 · $20 Meals for Imfinzi · 2020-01-17 · $50 Travel for Imfinzi · 2020-01-17 · $270 Travel for Imfinzi · 2020-01-17 · $703
Genzyme	Libtayo	$2,575	1 payment Consulting for Libtayo · 2020-10-20 · $2,575
Merck Sharp & Dohme	Keytruda	$1,308	10 payments Meals for Keytruda · 2020-02-14 · $14 Travel for Keytruda · 2020-02-14 · $25 Meals for Keytruda · 2020-02-14 · $35 Meals for Keytruda · 2020-02-14 · $50 Meals for Keytruda · 2020-02-14 · $50 Meals for Keytruda · 2020-02-13 · $13 Travel for Keytruda · 2020-02-13 · $198 Travel for Keytruda · 2020-02-13 · $25 Travel for Keytruda · 2020-02-13 · $774 Meals for Keytruda · 2020-02-13 · $125

2019: $17,535

Sort by

Payments by company in 2019

Takeda Pharmaceuticals U.S.A.	Alunbrig	$9,598	5 payments Travel for Alunbrig · 2019-03-01 · $669 Travel for Alunbrig · 2019-03-01 · $45 Travel for Alunbrig · 2019-03-01 · $304 Consulting for Alunbrig · 2019-03-01 · $8,400 Meals for Alunbrig · 2019-03-01 · $180
E.R. Squibb & Sons L.L.C.	None	$4,592	7 payments Consulting · 2019-07-15 · $3,575 Meals · 2019-06-22 · $30 Meals · 2019-06-22 · $50 Meals · 2019-06-22 · $60 Meals · 2019-06-22 · $30 Travel · 2019-06-21 · $201 Travel · 2019-06-21 · $646
AstraZeneca Pharmaceuticals LP	Imfinzi	$1,663	1 payment Consulting for Imfinzi · 2019-06-20 · $1,663
Boehringer Ingelheim Pharmaceuticals	Gilotrif	$1,613	2 payments Consulting for Gilotrif · 2019-04-01 · $1,500 Meals for Gilotrif · 2019-02-21 · $113
Genentech USA	Avastin	$58	1 payment Meals for Avastin · 2019-09-05 · $58
Pfizer	Lorbrena	$11	1 payment Education for Lorbrena · 2019-10-31 · $11

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Merck Sharp & Dohme Corporation · A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer · 2020	Their institution	$312,421
Amgen Inc. · Amg 510 Ph1b Master Protocol 20190135 · 2024	Their institution	$276,944
Amgen Inc. · Amg 510 Ph1b Master Protocol 20190135 · 2023	Their institution	$226,705
Merck Sharp & Dohme Corporation · A Phase II,III Randomized Trial of Two Doses of Mk-3475 Sch 900475 Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer · 2020	Their institution	$151,602
Merck Sharp & Dohme LLC · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2022	Their institution	$124,404
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2024	Their institution	$112,191
Merck Sharp & Dohme Corporation · Keymaker U01 Master Study A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy Or With Pembrolizumab Alone in Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2021	Their institution	$109,627
Merck Sharp & Dohme LLC · Keymaker U01 Master Study A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy Or With Pembrolizumab Alone in Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2022	Their institution	$94,914
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2022	Their institution	$65,299
Merck Sharp & Dohme LLC · Keymaker U01 Master Study# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy Or With Pembrolizumab Alone in Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2023	Their institution	$61,884
Merck Sharp & Dohme Corporation · A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer · 2019	Their institution	$59,455
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2023	Their institution	$53,921
Merck Sharp & Dohme Corporation · A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- Mk-3475, Sch 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer Keynote-495 Keyimpact · 2021	Their institution	$48,554
Amgen Inc. · A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Advanced Solid Tumors With Kras P.G12c Mutation (Codebreak 101) · 2025	Their institution	$47,596
Merck Sharp & Dohme Corporation · A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer · 2020	Their institution	$42,717
Merck Sharp & Dohme Corporation · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2021	Their institution	$35,775
Merck Sharp & Dohme LLC · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2024	Their institution	$34,937
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Sm · 2021	Their institution	$34,928
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2025	Their institution	$33,944
Merck Sharp & Dohme LLC · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2024	Their institution	$28,710
Merck Sharp & Dohme Corporation · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2019	Their institution	$26,403
Genentech, Inc. · Ph II Personalized Cancer Vaccine in Nsclc · 2021	Their institution	$23,940
Merck Sharp & Dohme Corporation · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2021	Their institution	$23,242
Merck Sharp & Dohme LLC · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2022	Their institution	$22,459
Merck Sharp & Dohme LLC · Keymaker-U01 Master Study# A Phase 1,2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone Or in Combination, in Participants With Non-Small Cell Lung Cancer Nsclc · 2024	Their institution	$16,758
Amgen Inc. · Amg 510 Ph3 Nsclc Monotherapy Comparator Trial · 2021	Their institution	$16,752
Merck Sharp & Dohme Corporation · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2020	Their institution	$16,682
Merck Sharp & Dohme LLC · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2023	Their institution	$16,021
Merck Sharp & Dohme LLC · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2023	Their institution	$15,040
Amgen Inc. · Amg 510 I12 Screening Kras G12c Protocol Pan Tumor · 2021	Their institution	$12,842
Merck Sharp & Dohme Corporation · A Phase II,III Randomized Trial of Two Doses of Mk-3475 Sch 900475 Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer · 2021	Their institution	$11,828
Amgen Inc. · P3 2l Nsclc Mono Comparator · 2022	Their institution	$8,282
Merck Sharp & Dohme Corporation · A Randomized Double-Blind, Phase III Study of Platinumpemtrexed Chemotherapy With Or Without Pembrolizumab Mk-3475 in First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer Subjects Keynote-189 · 2019	Their institution	$8,273
Merck Sharp & Dohme LLC · A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- Mk-3475, Sch 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer Keynote-495 Keyimpact · 2022	Their institution	$5,653
Amgen Inc. · Amg 510 - Adv. Kras G12c Solid Tumors 20190135 · 2021	Their institution	$3,508
Merck Sharp & Dohme LLC · A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- Mk-3475, Sch 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer Keynote-495 Keyimpact · 2023	Their institution	$3,460
Merck Sharp & Dohme Corporation · A Phase I,II Study of Mk-3475 Sch900475 in Combination With Chemotherapy and,Or Immunotherapy in Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Carcinoma · 2020	Their institution	$1,718
Amgen Inc. · Amg 510 Ph1b Master Protocol 20190135 · 2022	Their institution	$1,556
Merck Sharp & Dohme Corporation · Keymaker U01 Substudy 3 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer Nsclc Previously Treated With Anti-Pd-L1 Therapy · 2020	Their institution	$1,483
Merck Sharp & Dohme Corporation · Keymaker U01substudy 1 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2020	Their institution	$1,450
Merck Sharp & Dohme Corporation · Keymaker U01substudy 2 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Na Ve Patients With Pd-L1 Positive Advanced Non-Small Cell Lung Cancer Nsclc · 2020	Their institution	$1,231
Merck Sharp & Dohme Corporation · A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy Or With Pembrolizumab Alone in Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2019	Their institution	$656
Merck Sharp & Dohme Corporation · Keymaker U01 Master Study A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy Or With Pembrolizumab Alone in Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2020	Their institution	$215
Merck Sharp & Dohme LLC · A Phase II,III Randomized Trial of Two Doses of Mk-3475 Sch 900475 Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer · 2022	Their institution	$91
Merck Sharp & Dohme Corporation · Keymaker U01substudy 1 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2021	Their institution	$3
Merck Sharp & Dohme LLC · Keymaker U01substudy 1 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer Nsclc · 2022	Their institution	$2

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 75.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1194923235
Licence: CA A98645California A98645: Current · expires 2028-09-30
Trained: Stanford University School of Medicine, 2005 · 21 years ago
Group: University of California San Francisco · Regents of the University of California
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Internal medicine (207R00000X)
Mailing address: 269 Campus Dr, Division of Oncology, Ccsr, Room 1145, Stanford, CA, 94305
NPI first listed: 2007-07-10
NPI last updated: 2010-02-15

This is when the NPI record was last certified, not a medical board exam.